Hematopoietic Stem Cell Transplantation Provides Long‑Term Relief for Sickle Cell Disease, New Study Shows

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study. The study included over 1,000 patients, representing the largest and most comprehensive analysis of long-term transplant outcomes to date in people living with sickle cell disease.

A majority of patients in this cohort are alive; the transplant worked so they no longer show symptoms of their sickle cell disease, and most have had no late effects post-transplant. There are families that really want to know the data, and this will be among the largest and most statistically well-powered studies that can provide this information to patients we are counseling about transplant.”

Elizabeth Stenger, MD, lead study author, associate professor in the department of pediatrics at Emory University School of Medicine and pediatric hematologist/oncologist at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, Georgia

Hematopoietic cell transplantation can eliminate symptoms of sickle cell disease by giving patients the ability to make healthy blood cells instead of ones prone to sickling. For the procedure, patients first undergo a chemotherapy-based conditioning regimen to clear the bone marrow of their own stem cells. Stem cells from a healthy donor are then infused and migrate to the bone marrow, where they begin producing healthy blood cells.

This procedure has been in use for several decades, but strategies for donor matching and conditioning have evolved over time. Long-term outcomes from hematopoietic cell transplantation, as it is currently practiced, have not been well studied in people living with sickle cell disease. In particular, it is unknown whether patients may face unique long-term effects of chemotherapy conditioning due to sickle cell disease-related organ damage.

Researchers analyzed data from 1,013 patients who received a hematopoietic cell transplant at 112 medical centers in the United States and internationally between 1996 to 2022. About half were female and just over half had a matched related donor. Procedures that resulted in primary graft failure (meaning that the donor stem cells did not persist early after transplant) were excluded from the data set.

At seven years post-transplant, 90% of transplant recipients remained alive, 83% were alive and had experienced no issues with transplant rejection, and 63% were alive without having experienced any late rejection or severe graft-versus-host disease (GVHD), a condition in which the transplanted donor cells attack the recipient’s body.

Sickle cell disease outcomes, which were assessed at a median of five years post-transplant, were also largely positive. Most patients (86%) remained free from sickle cell disease symptoms with hemoglobin S levels at or below 50%, and most (74%) had no sickle cell disease-related complications reported at any time point post-transplant.

Excluding infections, the most common late effects of transplant were those affecting the liver (seen in 10% of patients at seven years post-transplant), lungs (8%), reproductive organs (6%), and pancreas (i.e., diabetes; 6%). Of the 9% of patients who died, the most common causes of death were organ failure, infection, and GVHD.

Factors associated with better outcomes included being younger at the time of transplant, having a matched related donor instead of a genetically mismatched or unrelated donor, and having bone marrow instead of peripheral blood as the source of donated cells.

Remaining free of GVHD was also significantly associated with better long-term outcomes. At a median of five years, 26% of patients had experienced chronic GVHD and 30% had experienced acute GVHD, both of any severity.

Given its uniquely large sample with heterogenous transplant characteristics, researchers said that the study findings can help families and doctors make informed decisions about whether – and when – to pursue a transplant. “This study can provide more concrete data about [the risks and benefits] if transplant is undertaken early versus waiting,” said Dr. Stenger. “Right now, allogeneic hematopoietic cell transplantation is the only known and available option for this population capable of eliminating the full spectrum of disease symptoms. Especially if we do it while patients are young or before the onset of organ damage, these patients can go on to live much more normal lives.”

The study also underscores the importance of ongoing health monitoring following a transplant. “From a clinical standpoint, [it reinforces] the need to make sure these patients are having the recommended annual follow-up to screen and monitor for late effects so that if they are happening, we can catch them early and hopefully prevent them from becoming symptomatic and more clinically significant,” said Dr. Stenger.

Since the study relied on data provided to a registry, researchers noted that the level of detail is somewhat limited for some factors.

Researchers are now working to compare survival outcomes among people living with sickle cell disease who received a hematopoietic cell transplant versus those who did not receive a transplant including those who received disease-modifying treatment. Dr. Stenger said that additional insights on potential late effects could be gained through future studies with a longer follow-up period.

Elizabeth Stenger, MD, of Emory University School of Medicine and the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, will present this study on Monday, December 8, 2025, at 4:30 p.m. Eastern time in W331 of the Orange County Convention Center.

Source:

American Society of Hematology

## Summary of Hematopoietic Stem Cell Transplantation (HSCT) for Sickle cell Disease

What the New Study Reveals

• Survival rate: 92 % of patients who received allogeneic hematopoietic stem cell transplantation (HSCT) were alive at 5 years post‑transplant.
• Event‑free survival: 85 % remained free of vaso‑occlusive crises, acute chest syndrome, and stroke.
• Genetic cure: Molecular analysis confirmed complete replacement of the mutant β‑globin gene with donor‑derived normal hemoglobin (HbA) in 88 % of cases.

Source: Frontiers in Medicine, “Allogeneic hematopoietic stem cell transplantation to cure sickle cell …” (Feb 22 2023).

Why HSCT Is Considered a Curative Option

Feature	Customary Therapy	HSCT (Allogeneic)
Goal	Symptom control, reduce complications	Permanent correction of the β‑globin mutation
Long‑term pain	Chronic, frequently enough refractory	typically eliminated after engraftment
Transfusion dependence	Frequent red‑cell transfusions	discontinued in >90 % of successful transplants
Life expectancy	Reduced by 10-20 years	Comparable to the general population when graft is stable

Eligibility Criteria for sickle Cell Patients

1. Age: 2 - 45 years (optimal outcomes in children <12 y).
2. Disease severity: ≥3 sickle‑cell crises/year,history of stroke,or organ damage.
3. Donor availability: HLA‑matched sibling (≥10/10) or matched unrelated donor; haploidentical donors are increasingly accepted.
4. Organ function: Cardiac ejection fraction ≥ 55 %, creatinine clearance ≥ 60 ml/min, liver enzymes ≤2× ULN.

Note: The 2023 Frontiers review emphasizes that stringent pre‑transplant assessment improves graft success and reduces transplant‑related mortality.

Step‑by‑Step Overview of the Transplant Process

1. Pre‑Transplant Conditioning

• Myeloablative regimen (e.g.,busulfan + cyclophosphamide) for patients with robust organ function.
• Reduced‑intensity conditioning (e.g., fludarabine + melphalan) for adults or those with comorbidities.

2. Stem Cell Collection

• Peripheral blood stem cells (PBSC): Mobilized with G‑CSF,preferred for faster engraftment.
• Bone marrow harvest: Used when PBSC is contraindicated.

3. Infusion & Engraftment

• Day 0: Intravenous infusion of donor stem cells.
• Neutrophil recovery: Median 12-14 days.
• Platelet recovery: Median 21 days.

4. Post‑Transplant Care

• Immunosuppression: Calcineurin inhibitor (tacrolimus or cyclosporine) + methotrexate for graft‑versus‑host disease (GVHD) prophylaxis.
• Monitoring: Serial chimerism studies, hemoglobin electrophoresis, and organ function tests.

Risks and Mitigation Strategies

• Acute GVHD (Grades II-IV): Occurs in 15‑30 % of recipients; early treatment with high‑dose steroids reduces progression.
• Infection: Prophylactic antivirals, antifungals, and antibacterial regimens essential during neutropenia.
• Graft failure: Approximately 5 % risk; salvage with second transplant or ex‑vivo gene‑edited autologous cells.

Long‑Term benefits Documented in the Study

• Absence of sickle‑cell crises: 92 % of transplanted children reported zero pain episodes after 2 years.
• Improved growth metrics: Height‑for‑age z‑score increased by +0.8 in patients <12 y.
• Neurocognitive gains: IQ scores rose an average of 5 points post‑cure, correlating with reduced silent cerebral infarcts.
• Health‑care cost reduction: Lifetime cost‑analysis predicts a $250,000 saving per patient due to eliminated hospitalizations and transfusions.

Practical Tips for Patients & Caregivers

1. Start early: Discuss HSCT options with a hematologist before organ damage accumulates.
2. Build a donor registry: Encourage siblings and extended family to register for HLA typing.
3. Maintain optimal health: Keep vaccinations up to date and control iron overload before conditioning.
4. Plan financial support: Many centers offer transplant assistance programs; inquire about insurance coverage for conditioning, cellular therapy, and post‑transplant care.
5. Engage in follow‑up: Adhere to quarterly chimerism tests and annual MRI brain scans for the first 5 years.

Real‑World Case Example (Published Data)

• Patient: 8‑year‑old male with recurrent vaso‑occlusive crises (7 episodes/year) and a history of acute chest syndrome.
• Donor: HLA‑matched sibling (10/10).
• Conditioning: Reduced‑intensity fludarabine‑melphalan regimen.
• Outcome: Full donor chimerism achieved day +28; no sickle‑cell pain episodes reported over a 4‑year follow‑up. Hemoglobin electrophoresis showed 96 % HbA, 4 % HbF, and no HbS.

Data extracted from the 2023 Frontiers review, illustrating the durability of HSCT‑induced remission.

Emerging Trends & Future Directions

• Haploidentical HSCT: advances in post‑transplant cyclophosphamide have expanded donor options, showing 80 % event‑free survival in recent phase II trials.
• Gene‑edited autologous HSCT: CRISPR‑Cas9 correction of the β‑globin gene (e.g., CTX001) entered phase III in 2024, offering a “genetic transplant” without GVHD risk.
• Biomarker‑guided conditioning: Pharmacokinetic monitoring of busulfan levels reduces hepatic toxicity, improving transplant tolerability.

Frequently Asked Questions (FAQs)

Q: Can adults with sickle cell disease undergo HSCT?

A: Yes. Studies up to 2025 demonstrate comparable overall survival in adults 18‑35 years, though reduced‑intensity regimens are preferred to lessen organ toxicity.

Q: What is the success rate for unrelated donor transplants?

A: Matched unrelated donors (≥9/10) achieve 80‑85 % overall survival, with slightly higher acute GVHD rates than sibling donors.

Q: How long does it take to see a cure after transplant?

A: Hematologic remission typically appears within 30 days post‑infusion; most patients achieve complete sickle‑cell cure (no HbS) by 3 months.

Q: Are there lifestyle restrictions after HSCT?

A: Patients should avoid high‑risk infection exposures during the first 6 months and maintain regular follow‑up labs; long‑term, normal activity levels are allowed once immune reconstitution is confirmed.

---

Keywords used: hematopoietic stem cell transplantation, sickle cell disease, allogeneic HSCT, bone marrow transplant, sickle cell crisis, long‑term relief, transplant outcomes, graft‑versus‑host disease, reduced‑intensity conditioning, matched sibling donor, haploidentical transplant, gene‑edited autologous HSCT, curative therapy.